Abcam (LON:ABC) PT Lowered to GBX 1,700

Abcam (LON:ABCGet Rating) had its price target reduced by Royal Bank of Canada from GBX 1,950 ($24.04) to GBX 1,700 ($20.96) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. They currently have an outperform rating on the stock.

ABC has been the subject of a number of other reports. JPMorgan Chase & Co. lowered their price target on shares of Abcam from GBX 1,800 ($22.19) to GBX 1,500 ($18.49) and set a neutral rating for the company in a report on Wednesday, March 16th. Berenberg Bank reiterated a hold rating and set a GBX 1,400 ($17.26) price target on shares of Abcam in a report on Wednesday, March 16th. Finally, Liberum Capital lowered their target price on shares of Abcam from GBX 1,450 ($17.88) to GBX 1,250 ($15.41) and set a hold rating for the company in a report on Monday, February 28th.

Shares of ABC opened at GBX 1,085 ($13.38) on Tuesday. The stock has a market cap of £2.48 billion and a P/E ratio of 571.05. Abcam has a 12-month low of GBX 1,013.57 ($12.50) and a 12-month high of GBX 1,760 ($21.70). The company has a current ratio of 1.13, a quick ratio of 0.79 and a debt-to-equity ratio of 17.41. The company has a 50-day moving average of GBX 1,308.07 and a two-hundred day moving average of GBX 1,436.60.

In other Abcam news, insider Michael Baldock purchased 5,910 shares of Abcam stock in a transaction on Wednesday, March 16th. The shares were purchased at an average cost of GBX 1,700 ($20.96) per share, with a total value of £100,470 ($123,868.82). Also, insider Mara G. Aspinall bought 3,037 shares of Abcam stock in a transaction dated Monday, April 4th. The shares were purchased at an average cost of GBX 1,436 ($17.70) per share, for a total transaction of £43,611.32 ($53,768.12).

About Abcam (Get Rating)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.

Featured Stories

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.